Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Aggression × glofitamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 18 Lymphoma, Mantle-Cell 9 Recurrence 8 Lymphoma, Non-Hodgkin 8 Lymphoma, B-Cell 7 Lymphoma 6 Dendritic Cell Sarcoma, Interdigitating 2 Neoplasms 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Cytokine Release Syndrome 1 Ann Arbor Stage II Mantle Cell Lymphoma 1 Aggression 1

Interventions

vandetanib 1 selinexor 1 pegfilgrastim 1 midostaurin 1 glofitamab 1 Topotecan 1 Rituximab 1 Prednisone 1 Positron Emission Tomography Computed Tomography 1 Paclitaxel 1 Methylprednisolone 1 Immunologic Techniques 1 Ifosfamide 1 Flow Cytometry 1 Etoposide 1 Dexamethasone 1 Carboplatin 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06534437 2025-09-29

JASPIS-01

Ryvu Therapeutics SA

Phase 2 Recruiting

Aggression, Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡